Gary Patou - 23 Nov 2022 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Cassandra Robinson, Attorney-in-Fact
Issuer symbol
XENE
Transactions as of
23 Nov 2022
Net transactions value
-$136,612
Form type
4
Filing time
28 Nov 2022, 19:41:46 UTC
Previous filing
29 Jun 2022
Next filing
02 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Sale $70,610 -2,057 -8% $34.33 23,573 23 Nov 2022 Direct F1
transaction XENE Common Shares Options Exercise $5,513 +2,057 +8.7% $2.68 25,630 25 Nov 2022 Direct F2
transaction XENE Common Shares Tax liability $4,124 -120 -0.47% $34.37 25,510 25 Nov 2022 Direct F3
transaction XENE Common Shares Sale $67,390 -1,937 -7.6% $34.79 23,573 25 Nov 2022 Direct F4
holding XENE Common Shares 12,500 23 Nov 2022 See Note F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -2,057 -100% $0.000000* 0 25 Nov 2022 Common Shares 2,057 $2.68 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $34.24 to $34.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2 The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F3 Represents the closing price of the Company's common shares on November 23, 2022 for purposes of net settlement calculations.
F4 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $34.76 to $34.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
F6 The shares subject to the option are fully vested and exercisable.